Confronto

AOD-9604 vs. Sermorelin

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Crescita

N. CAS

221231-10-3

86168-78-7

Peso molecolare

1815.09 g/mol

3358 g/mol

Emivita

0.4 h

0.2 h

Sequenza

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

YADAIFTNSYRKVLGQLSARKLLQDIMSR

Meccanismo d'azione

AOD-9604

AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.

Sermorelin

Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	AOD-9604	Sermorelin
Australia	Limitato	—
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Solo ricerca

Voci complete

Frequently asked questions

What is the difference between AOD-9604 and Sermorelin?: AOD-9604 is classified as "Crescita", while Sermorelin is classified as "Crescita". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. Sermorelin: Synthetic analogue of the first 29 amino acids of human GHRH. Stimulates pulsatile growth-hormone secretion from the pituitary. Formerly FDA-approved as Geref Diagnostic, now withdrawn in many markets — compounding and research use dominate. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, AOD-9604 or Sermorelin?: The highest available evidence level is "RCT sull'uomo" for AOD-9604 and "RCT sull'uomo" for Sermorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of AOD-9604 and Sermorelin in Germany and the United States?: Germania: AOD-9604 — Non approvato, Sermorelin — Non approvato. Stati Uniti: AOD-9604 — Non approvato, Sermorelin — Solo ricerca. These are factual summaries with source and review date on the individual pages.

Country

AOD-9604

Sermorelin

Australia

Limitato

—

Germania

Non approvato

Stati Uniti

Non approvato

Solo ricerca

Frequently asked questions

What is the difference between AOD-9604 and Sermorelin?

AOD-9604 is classified as "Crescita", while Sermorelin is classified as "Crescita". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. Sermorelin: Synthetic analogue of the first 29 amino acids of human GHRH. Stimulates pulsatile growth-hormone secretion from the pituitary. Formerly FDA-approved as Geref Diagnostic, now withdrawn in many markets — compounding and research use dominate. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, AOD-9604 or Sermorelin?

The highest available evidence level is "RCT sull'uomo" for AOD-9604 and "RCT sull'uomo" for Sermorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of AOD-9604 and Sermorelin in Germany and the United States?

Germania: AOD-9604 — Non approvato, Sermorelin — Non approvato. Stati Uniti: AOD-9604 — Non approvato, Sermorelin — Solo ricerca. These are factual summaries with source and review date on the individual pages.